#United States #Dallas #Lilly #EBGLYSS #Senderra

Enhancing Patient Care: The Launch of EBGLYSS at Senderra Specialty Pharmacy

In a significant advancement for patients battling moderate to severe atopic dermatitis, Senderra Specialty Pharmacy proudly announces the integration of EBGLYSS™ (lebrikizumab-lbkz) into its SenderraCare+ platform. This biologic treatment, developed by Lilly, is a crucial resource for adults and pediatric patients aged 12 and above who struggle to manage their condition with traditional topical therapies. With this step, Senderra aims to elevate the patient care experience through innovative digital solutions.

A Transformative Digital Experience

The SenderraCare+ platform is not just a prescription service; it redefines how specialty therapy is accessed and managed. The platform's intuitive design consolidates various aspects of patient care into a single, user-friendly interface. This encompasses enrollment processes, adherence support, and medication management, allowing patients to engage in their healthcare journey like never before.

Real-Time Engagement

One of the standout features of SenderraCare+ is its provision for real-time updates regarding medication status. Patients can communicate directly through the platform, receiving timely notifications and alerts about their therapies. This two-way communication approach significantly mitigates the frustration often associated with managing chronic conditions and empowers patients by keeping them informed and involved.

Accelerating Treatment Initiation

Prompt initiation of treatment is crucial in managing health conditions effectively. With the integration of EBGLYSS, patients can now begin their therapeutic journey immediately after leaving their healthcare provider's office. Thanks to a digital SMS enrollment option, patients can easily submit their details, schedule welcome calls, and even dictate their medication delivery preferences through a secure, streamlined process. This user-centric approach aims to minimize delays in treatment while enhancing patient compliance.

Empowering Patients and Healthcare Providers

Senderra's innovative model doesn't just benefit patients. Healthcare providers also see tangible advantages through the SenderraCare+ platform. By handling complexities such as prior authorization for prescriptions, Senderra frees up valuable time for healthcare provider offices. This ensures a smoother experience not only for patients but also for the medical professionals overseeing their care.

As Will Howard, CEO and Co-Founder of Senderra, emphasizes, "Integrating EBGLYSS into our SenderraCare+ platform is a game changer for patient-focused specialty care. Our commitment to innovation continually enhances the experience for patients and providers alike, driving us to find solutions that cater to their needs efficiently and effectively."

Addressing Key Healthcare Challenges

The introduction of EBGLYSS into SenderraCare+ provides a robust solution to several challenges faced by patients utilizing specialty medications. These include high abandonment rates of prescribed treatments and difficulties with adherence to complex medication regimens. The interactive nature of the platform seeks to alleviate these issues, ensuring patients remain engaged and supported throughout their therapy.

Conclusion

With the launch of EBGLYSS, Senderra Specialty Pharmacy stands at the forefront of patient-centered care. By leveraging technology to improve healthcare experiences, they are setting new standards in specialty pharmacy services. This integration signifies a commitment not only to pushing boundaries in pharmaceutical care but also to ensuring that every patient receives the quality care they deserve. Senderra supports over 12,000 providers nationally, showcasing its far-reaching impact in the specialty pharmacy sector. For more information on their services, visit Senderra's website.